在跨导管大动脉置换中导航出血,血栓和抗血栓治疗
Jude Elsaygh1, Manish A Parikh1,2, William H Frishman3
1From the Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY.
Cardiology in review
|May 13, 2025
概括
在过导管大动脉置换 (TAVR) 后管理抗血栓治疗是复杂的. 本综述审查了指导方针和数据,以优化TAVR患者的出血和血栓形成风险.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 血管医学 血管医学
背景情况:
- 过导管大动脉置换 (TAVR) 是对大动脉狭窄的不那么侵入性治疗方法.
- 在TAVR后的管理带来了挑战,特别是在抗血栓策略方面,因为有竞争性出血和血栓形成的风险.
研究的目的:
- 审查TAVR患者目前的抗血栓治疗策略.
- 检查指导方针,临床数据和直接口服抗凝剂的作用.
- 讨论TAVR患者心房动和冠状动脉疾病等并发症的管理.
主要方法:
- 美国和欧洲指南的文献综述.
- 对抗凝血和抗血小板治疗的临床试验数据的分析.
- 探索直接口服抗凝剂在TAVR中的作用.
主要成果:
- 目前的指导方针为TAVR后的抗血栓治疗提供了不同的建议.
- 个性化方法至关重要,考虑到患者特定的风险和并发症.
- 直接口服抗凝剂显示有前途,但需要在TAVR群体中进一步研究.
结论:
- 在TAVR后优化抗血栓治疗需要平衡出血和血栓风险.
- 需要进一步的研究来完善建议并改善患者的治疗结果.
- 个性化管理策略是缓解中风和出血等并发症的关键.
更多相关视频
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
548
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
548
Esophageal Varices-II: Clinical Features and Management
27
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
27
Disorders of Hemostasis
651
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
651
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
396
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
396
Clot Retraction and Fibrinolysis
2.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.9K


